Endometrial claudin-4 and leukemia inhibitory factor are associated with assisted reproduction outcome by Serafini, Paulo C et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
Reproductive Biology and 
Endocrinology
Open Access Research
Endometrial claudin-4 and leukemia inhibitory factor are associated 
with assisted reproduction outcome
Paulo C Serafini*†1,2, Ismael DCG Silva3, Gary D Smith4, 
Eduardo LA Motta2,3, André M Rocha2 and Edmund C Baracat†1
Address: 1Department of Gynecology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, 2Huntington Reproductive Medicine, 
São Paulo, Brazil, 3Department of Gynecology, Universidade Federal de São Paulo, São Paulo, Brazil and 4Department of Obstetrics and 
Gynecology, Urology, Physiology, and Reproductive Science Program, University of Michigan, Ann Arbor, USA
Email: Paulo C Serafini* - pserafini@huntington.com.br; Ismael DCG Silva - isamel.toco@epm.br; Gary D Smith - smithgd@umich.edu; 
Eduardo LA Motta - emotta@huntington.com.br; André M Rocha - arocha@huntington.com.br; Edmund C Baracat - ecbaracat@hotmail.com
* Corresponding author    †Equal contributors
Abstract
Background: Claudin-4 (CLDN4) is one of several proteins that act as molecular mediators of
embryo implantation. Recently, we examined immunolabeling of leukemia inhibitory factor (LIF) in
the endometrial tissue of 52 IVF patients, and found that LIF staining intensity was strongly
correlated with successful pregnancy initiation. In the same set of patients, we have now examined
endometrial CLDN4 expression, to see how expression intensity may vary with LIF. We examined
CLDN4 in the luteal phase of the menstrual cycle, immediately preceding IVF treatment. Our aim
was to compare expression of LIF and CLDN4 in the luteal phase, and document these patterns as
putative biomarkers for pregnancy.
Methods: Endometrial tissue was collected from women undergoing IVF. Endometrial biopsies
were obtained during the luteal phase preceding IVF, and were then used for tissue microarray
(TMA) immunolabeling of CLDN4. Previously published LIF expression data were then combined
with CLDN4 expression data, to determine CLDN4/LIF expression patterns. Associations
between successful pregnancy after IVF and combined CLDN4/LIF expression patterns were
evaluated.
Results: Four patterns of immunolabeling were observed in the endometrial samples: 16% showed
weak CLDN4 and strong LIF (CLDN4-/LIF+); 20% showed strong CLDN4 and strong LIF (LIF+/
CLDN4+); 28% showed strong CLDN4 and weak LIF (CLDN4+/LIF-); and 36% showed weak
CLDN4 and weak LIF (CLDN4-/LIF-). Successful implantation after IVF was associated with
CLDN4-/LIF+(p = 0.003). Patients showing this endometrial CLDN4-/LIF+ immunolabeling were
also 6 times more likely to achieve pregnancy than patients with endometrial CLDN4+/LIF-
immunolabeling (p = 0.007).
Conclusion: The combined immunolabeling expression of CLDN4-/LIF+ in endometrial tissue is a
potential biomarker for predicting successful pregnancy in IVF candidates.
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Background
Embryonic implantation takes place on the uterine inner
surface after a series of molecular and cellular interactions
between the embryo and endometrium. Shedding of the
zona pellucida, the apposition of the embryo to the
endometrium, and embryonic invasion into the endome-
trial glandular epithelium and stroma, are all governed by
multiple factors and highly active mechanisms [1]. Several
types of proteins act as mediators of implantation [2],
such as intracellular signal transducers, growth and differ-
entiation factors, receptors, and cell surface adhesion mol-
ecules [3]. Furthermore, these proteins are responsible for
the differentiation of endometrium, which facilitates
embryo adhesion and invasion, gates infiltrating natural
killer cells, and maintains the intercellular milieu [1].
Claudin-4 (CLDN4), initially named Clostridium perfrin-
gens enterotoxin receptor (CPER), may have an important
role in implantation [4-6]. CLDN4 is a tetraspan protein
with 27 kDa and shorter amino and carboxy terminals [7].
The claudin family is composed of more than 20 claudins
[8] that are present in tight junctions, where they form
aqueous and ion-selective aqueous pores [9,10].
Claudin-4 mRNA and protein show different patterns of
expression during different cycle stages. cDNA microarray
analysis of the midluteal phase endometrial transcrip-
tome revealed increased CLDN4 mRNA, compared to
other luteal phase stages (4–6). However, immunohisto-
chemical analysis of CLDN4 protein expression in the
endometrium during the secretory phase was weak or neg-
ative [11]. To date, there are no reports on the functional
roles of CLDN4 during the implantation process, for
either spontaneous or in vitro fertilization (IVF) pregnan-
cies.
Recently, we examined luteal phase immunolabeling of
endometrial leukemia inhibitory factor (LIF) prior to IVF
treatment [12]. We found that strong endometrial LIF
immunolabeling was associated with pregnancy. In fact,
women expressing strong endometrial LIF immunolabe-
ling were 6.4 times more likely to initiate a pregnancy
than those with weak or absent LIF immunolabeling. The
expression pattern of this cytokine during the menstrual
cycle [13,14], and previous clinical associations between
LIF deficiency and infertility [15], suggest LIF has a possi-
ble role in the implantation phenomenon.
The primary goal of the current study was to evaluate
endometrial CLDN4 expression as a biomarker for preg-
nancy. Thus, we focused on endometrial CLDN4 immu-
nolabeling in the luteal phase of the menstrual cycle,
immediately preceding IVF treatment. In addition, we
examined the association between endometrial CLDN4
and LIF immunolabeling.
Methods
Patients
The patients followed in this study were infertile women
undergoing IVF treatments between July 2004 and August
2006. Briefly, all subjects were screened and assessed
according to ASRM guidelines, with a detailed medical
history, physical exam, and laboratory workup [16,17].
All participants had indications for IVF, and were coun-
seled regarding the nature and purpose of the study.
Approval for this research was obtained from both the
Ethics Committee of the Department of Gynecology, and
the Institutional Review Board of the Faculdade de Medic-
ina da Universidade de São Paulo. All patients signed an
informed consent form.
Eligibility criteria for inclusion in the study were: 1) pres-
ence of two functional ovaries; 2) an anatomically normal
uterine cavity on the basis of recent hysterosalpingogram
or hysteroscopy (≤ 6 months); 3) history of ≤ 3 attempts
at IVF/ICSI; 4) early follicular phase (day 2 or 3) serum
Follicle Stimulating Hormone (FSH) levels of ≤ 15 IU/L;
5) estradiol (E2) levels that were ≤ 60 pg/mL; 6) ho his-
tory of negative or low ovarian response in previous IVF/
ICSI treatment; 7) body mass index (BMI) ≤ 28 kg/m2; 8)
no treated endocrinologic disease; and 9) no gonadotro-
pin therapy for the prior 3 months.
Endometrial biopsy tissue processing
As previously described, endometrial biopsies were per-
formed in an outpatient facility [12]. Briefly, after confir-
mation of ovulation by ultrasound examination at mid
cycle, and when day 21 serum progesterone concentration
was ≥ 3 ng/dL, endometrial biopsies were collected with a
Pipelle endometrial suction curette (Pipelle de Cornier,
Cooper Surgical, USA). Each patient was submitted to one
biopsy collected during one of the three phases of the
menstrual cycle: early (day 16–19), middle (day 20–24)
and late (day 25–28), as well as immediately prior to
commencement of GnRHa therapy. Endometrial tissue
samples were fixed in formalin, then embedded in paraf-
fin. Tissue blocks were sectioned at 3 – 4 μm, then proc-
essed for: 1) endometrial dating according to Noyes
criteria [18], and 2) immunohistochemical labeling of
CLDN4, described below.
Tissue microarray and immunohistochemical analysis
To perform TMA analysis, 1 mm endometrial tissue sam-
ples were obtained from paraffin donor blocks represent-
ing the three different luteal stages of the luteal phase.
Samples were acquired with a TMArrayer™ punch MP10-
1.0 mm (Pathology Devices INC., USA), and arranged in
the TMArrayer™ recipient block of 15 × 10 cores. Two
cores of human prostate tissue were also included in the
TMArrayer™ as positive controls for CLDN4 expression.
All endometrial tissue samples were sectioned at 3–4 μm,Reproductive Biology and Endocrinology 2009, 7:30 http://www.rbej.com/content/7/1/30
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then mounted on glass slides for CLDN4 immunohisto-
chemistry [12].
Immunohistochemical labeling for CLDN4 was per-
formed on 3 sections from each sample. For antigen
retrieval, slides were incubated in citric acid solution (10
mM, pH 6.0) and processed in a microwave (1300 watts)
for nine minutes [12]. Slides were washed in distilled
water, and blocked in phosphate buffered saline (PBS)
with blocking serum (10%). Slides were then incubated in
primary antibody, a 1:200 dilution of rabbit polyclonal
anti-CLDN4 (C-18: sc-17664, Santa Cruz Biotechnology
INC., USA) in PBS supplemented with 2% of blocking
serum for one hour at room temperature. Slides were then
rinsed with PBS for 5 minutes, and incubated in a 1:200
dilution of goat anti-rabbit secondary antibody, linked to
a streptavidin-biotin-peroxidase complex (StreptABCom-
plex, DAKO, Denmark). The peroxidase was then exposed
to a solution of diaminobenzidine (DAB, Sigma, EUA) in
PBS, and allowed to react for 5 minutes, until the forma-
tion of a brown reaction product. Slides were then rinsed
in PBS, and counterstained with Harris Hematoxylin
(Merck, USA). After dehydration in a series of ethanols to
xylene, slides were coverslipped in Histomount medium.
For all samples, CLDN4 immunolabeling was compared
to positive prostate tissue controls by two experienced
pathologists blinded to the sample identity and the pur-
pose of the study. CLDN4 immunolabeling was scored
according to intensity and frequency, following the
method of Soini, with slight modifications [19]. The
CLDN4 immunolabel score was computed as a multipli-
cation of frequency × intensity, with results ranging
between 0 and 12. Four categories were designated within
this range of scores: negative (0 to 1.9); weak, (2.0 to 4.9);
mild, (5.0 to 8.9); and strong (9.0 to 12.0). These results
were then compared with endometrial LIF immunolabe-
ling data from the same study group, which were previ-
ously published [12].
Ovulation stimulation and IVF
The procedures for ovulation stimulation and IVF-ET have
also been previously described in detail [12]. Briefly,
patients were given daily subcutaneous injections of Leu-
prolide acetate (Lupron®, TAP Pharmaceuticals Products
Inc.), during the mid- and late luteal phases of the previ-
ous menstrual cycle, to cause pituitary desensitization.
Recombinant hFSH (Gonal-F®, Serono Laboratories) was
then administered, in doses ranging from 150–300 UI,
depending on patient age. The administration of the
GnRH agonist was extended until the final day of follicle
maturation, when at least 2 codominat follicles reach 18
mm. Subsequently, a maturational dose of recombinant
hCG (Ovidrel®, Serono Laboratories) was injected to
accommodate oocyte retrieval within 35–36 hours.
Oocyte harvesting was carried out in an outpatient facility,
under mild sedation and analgesia.
Following harvesting, oocyte fertilization procedures were
initiated. Oocyte identification, gamete preparation and
handling, insemination by ICSI, and embryo transfer,
have all been previously described [20]. Embryo scoring
was based on developmental stage and morphology,
using established criteria. Average cumulative embryo
scoring per transfer was calculated as the sum of trans-
ferred embryo scores/the total number transferred. All
embryo transfers were carried out on day 3. Luteal phase
hormonal support consisted of 1200 mg daily doses of
micronized progesterone, beginning on the day after
oocyte retrieval. A clinical pregnancy was defined by a pel-
vic ultrasound that showed a gestational sac with an
embryonic heart activity. Birth rate in the study popula-
tion was defined as the total successful births of a live
child, divided by IVF treatment.
Data analysis
A variety of statistical analyses were carried out to evaluate
associations between immunolabeling patterns and preg-
nancy. Statistical association between CLDN4 immunola-
bel score and pregnancy was assessed by Chi-square
analysis. To calculate an odds ratio for pregnancy, we used
a binary logistic regression. In addition, previously pub-
lished endometrial LIF immunolabeling data from the
same group of patients [12] were combined with CLDN4
immunolabeling data, to determine coincident CLDN4/
LIF expression patterns. Weak or mild immunolabeling
was considered negative (-), and strong immunolabeling
was considered positive (+). With this notation, combined
immunolabeling patterns were classified into four catego-
ries: 1) strong CLDN4 and strong LIF (LIF+/CLDN4+); 2)
strong CLDN4 and weak LIF (CLDN4+/LIF-); 3) weak
CLDN4 and strong LIF (CLDN4-/LIF+); 4) weak CLDN4
and weak LIF (CLDN4-/LIF-).
Associations between successful pregnancy after IVF and
each immunolabeling category were evaluated with Chi-
square or Fisher's exact test. These tests were also used to
determine association of immunolabeling patterns with
either histological stage of the luteal phase, or infertility
cause (endometriosis, polycystic ovary syndrome, tubal
patency failure and male infertility).
Statistically significant differences in the proportion of
pregnancy/non-pregnancy, and birth/non-birth among
the CLDN4/LIF immunolabeling categories were exam-
ined by a Z-test for two proportions. Frequencies of preg-
nancy and birth were tested for correlation by calculating
a Pearson's correlation coefficient (r).Reproductive Biology and Endocrinology 2009, 7:30 http://www.rbej.com/content/7/1/30
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In addition, general IVF parameters were tested for corre-
lation with immunolabeling patterns. First, women's age,
total rFSH dose, number of transferred embryos, number
of top quality embryos, and mean score per embryo were
submitted to a Kolgomov-Smirnov test, to assess normal
distribution, then an F-test, to assess data homogeneity.
Differences in immunolabeling patterns among pregnant
and non-pregnant women were compared by Student's t
test. These data among different immunolabeling catego-
ries were further compared by ANOVA and Tukey's test.
All data are expressed as mean ± standard deviation (SD),
and significance level was set at p < 0.05.
Results
CDLN4 immunolabel in stages of luteal phase
A total of 52 endometrial biopsy core samples were
obtained from the 52 women in the study group (mean
age, 35 ± 5 years). Across all phases, endometrial CLDN4
immunolabeling was mild in 16%, strong (Figure 1A) in
48% and absent in 36%.
All endometrial tissue samples were histologically defined
as either early luteal phase (n = 23), midluteal phase (n =
18), or late luteal phase (n = 11). Among early luteal
phase samples, CLDN4 immunolabeling was absent in
50% (n = 11) of patients, mild in 26% (n = 6), and strong
in 26% (n = 6). Among midluteal phase samples, CLDN4
immunolabeling was absent in 17% (n = 3) of patients,
mild in 11% (n = 2), and strong in 72% (n = 13). Among
late luteal phase samples, CLDN4 immunolabeling was
absent in 40% (n = 4), and strong in 60% (n = 7) of
patients. There was no association between CLDN4
expression and stage of luteal phase.
CDLN4 and infertility
Among the 52 patients, causes of infertility were: endome-
triosis (27%, n = 14), polycystic ovary syndrome (25%, n
= 13), tubal patency failure (13%, n = 7) and male infer-
tility (35%, n = 18). Infertility cause was not associated
with CLDN4 immunolabeling (p = 0.09) (Table 1); and,
neither with women who did not establish pregnancy (p
= 0.8). However, strong CLDN4 immunolabeling was
associated with failure to establish pregnancy after IVF (p
= 0.01). These patients were 10.5 times less likely to
achieve pregnancy than those with weak immunolabe-
ling.
A review of LIF immunolabeling in stages of luteal phase
CLDN4 immunolabeling was then compared to previ-
ously reported LIF immunolabeling. To review, LIF immu-
nolabel was weak in 5.8% (n = 3), mild in 61.5% (n = 32)
and strong (Figure 1B) in 32.7% (n = 17). Among early
luteal phase samples, 35% (n = 8) showed strong LIF
immunolabeling, while 60% (n = 14) showed mild, and
5% showed weak (n = 1). Of the midluteal samples, 50%
(n = 9) showed strong, 44% (n = 8) showed mild, and 6%
(n = 1) showed weak LIF immnolabeling (Figure 1B). Of
the late luteal phase samples, 82% (n = 9) showed mild,
18% (n = 2) showed strong, and none showed weak LIF
immunolabeling. There was no association between LIF
immunolabeling and stage of luteal phase. However, LIF
expression was associated with pregnancy, and patients
expressing strong LIF immunolabel in the endometrium
were 6.4 times likely to achieve pregnancy than those with
weak or mild staining [12].
Comparison of CLDN4 and LIF within each patient
We then compared the CLDN4 and LIF immunolabeling
data within each patient. Strong immunolabeling for LIF
was not associated with strong immunolabeling for
Examples of strong immunolabeling of A) CLDN4 and B) LIF Figure 1
Examples of strong immunolabeling of A) CLDN4 and B) LIF. C) The frequency of pregnancy, non-pregnancy, and 
birth, in patients from each of the four CLDN4/LIF endometrial immunolabeling categories.
Figure 1Reproductive Biology and Endocrinology 2009, 7:30 http://www.rbej.com/content/7/1/30
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CLDN4 (Table 2). Four patterns of immunolabeling were
observed in the endometrial samples: 16% showed weak
CLDN4 and strong LIF (CLDN4-/LIF+); 20% showed
strong CLDN4 and strong LIF (CLDN4+/LIF+); 28%
showed strong CLDN4 and weak LIF (CLDN4+/LIF-); and
36% showed weak CLDN4 and weak LIF (CLDN4-/LIF-).
CLDN4/LIF category and patient parameters
Immunolabeling patterns were then compared with
parameters of the patient population. There were no asso-
ciations between endometrial CLDN4/LIF immunolabe-
ling category and cause of infertility (Table 2; p = 0.165),
or stage of the luteal phase (p = 0.09). The overall preg-
nancy rate in the study group was 39% (n = 20).
Interestingly, there was an association between CLDN4-/
LIF+ immunolabeling category (p = 0.01) and pregnancy.
The frequency of pregnancy (fp) was higher than the fre-
quency of non pregnancy (fnp) in patients whose samples
showed endometrial CLDN4-/LIF+ immunolabeling (fp =
0.88; p = 0.035; 95% CI = 0.47; 0.99), and lower than fnp
in those with CLDN4+/LIF- immunolabeling (fp = 0.2; p =
0.013; 95% CI = 0.01; 0.40). The proportion of pregnant
and non-pregnant patients was similar between women
with endometrial CLDN4+/LIF+immunolabeling (fp =
0.6; p = 0.754; 95% CI = 0.26; 0.87) and CLDN4-/LIF-
immunolabeling (fp = 0.63; p = 0.359; 95% CI = 0.38;
0.83) (Figure 1c). Strikingly, patients with CLDN4-/LIF+
endometrial immunolabeling were 36 times more likely
to get pregnant, compared to those with CLDN4+/LIF-
immunolabeling (p = 0.007; 95% CI = 2.69, 481.23). In
addition, these CLDN4-/LIF+ patients were 10.29 times
more likely to achieve pregnancy than those with CLDN4-
/LIF-immunolabeling (p = 0.048; 95% CI = 1.02, 103.95).
Though these CLDN4-/LIF+ endometrial immunolabeling
patients were also 4 times more likely to achieve preg-
nancy than those with CLDN4+/LIF+immunolabeling,
this odds ratio was not significant (p = 0.27; 95% CI =
0.34, 47.11).
At the opposite extreme, patients exhibiting CLDN4+/LIF-
endometrial immunolabeling showed much less preg-
nancy success. These patients had 0.89 less chance of preg-
nancy than those with CLDN4+/LIF+ immunolabeling (p
= 0.028; 95% CI = 0.02, 0.79). Furthermore, patients
exhibiting CLDN4+/LIF-  endometrial immunolabeling
showed 0.71 less chance of pregnancy compared to those
with CLDN4-/LIF- immunolabeling, but this odds ratio
was not significant (p = 0.16; 95% CI = 0.05, 1.67).
And finally, the absence of immunolabel for either
CLDN4 or LIF (CLDN4-/LIF-) did not show a different
chance of pregnancy than those with strong immunolabel
for both proteins (vs. CLDN4+/LIF+, (p = 0.23; odds ratio
= 0.39; 95% CI = 0.08, 1.87). Data is summarized in table
3.
Birth rates and CLDN4/LIF immunolabeling category
The frequency of birth (fb) was correlated to fp in the
study group (r = 0.997; p = 0.003), so associations with
CLDN4/LIF endometrial immunolabeling followed a pat-
tern similar to those seen with fp. The fb was lower than
the frequency of non-birth (fnb) in patients with
CLDN4+/LIF- endometrial immunolabeling (fb = 0.16; p =
0.0001; 95% CI = -0.95; -0.45) and CLDN4-/LIF- immu-
nolabeling (fb = 0.27; p = 0.0001; 95% CI = -0.71; -0.19).
Also, the proportion of births was similar in women with
endometrial CLDN4-/LIF+ immunolabeling (fb = 0.71; p =
0.076; 95% CI = -0.04; 0.9), and CLDN4+/LIF+immunola-
beling (fb = 0.45; p = 0.635; 95% CI = -0.34; 0.57) (Figure
1C). Odds ratio for birth is summarized in table 4.
Overall patient statistics for IVF
We calculated mean IVF characteristics for the study
group. On average, patients experienced 1.51 ± 1.22 pre-
vious IVF cycles before consenting to this study. Ovarian
stimulation was accomplished with 2605.00 ± 995.00 UI
of rFSH, and an average of 3 ± 1 embryos were transferred.
Of the embryos transferred, 1 ± 1 was classified as top
Table 1: Distribution of infertility etiology identified among patients in the study among the CLDN4/LIF immunolabeling categories
CLDN4/LIF categories Infertility cause
Male factor Tubal factor Polycystic
ovary syndrome
Endometriosis
CLDN4+/LIF+ 32 1 3
CLDN4-/LIF+ 49 9 6
CLDN4+/LIF- 72 1 4
CLDN4-/LIF- 49 9 6
Table 2: Distribution of the number of patients among 
endometrial CLDN4/LIF immunolabeling intensities
Endometrial expression LIF+ LIF-
CLDN4+ 91 4
CLDN4- 72 2
Chi-square: 1.353 p = 0.245
Chi-square for association between positive and negative 
immunolabelings for CLDN4 and LIFReproductive Biology and Endocrinology 2009, 7:30 http://www.rbej.com/content/7/1/30
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quality, and the cumulative score/embryos transferred/
procedure was 20 ± 8.
We also compared characteristics of pregnant and non-
pregnant patients. Pregnant patients were typically
younger than non-pregnant patients (Table 2), and the
increase of one year in maternal age accounted for a 30%
decrease in pregnancy chances (p = 0.002). Similar among
pregnant and non-pregnant patients were: number of pre-
vious IVF cycles, rFSH dose required for Controlled Ovar-
ian Stimulation (COS), number of transferred embryos,
number of top quality transferred embryos, and the mean
embryo score (Table 5). These parameters were also simi-
lar among all CLDN4/LIF immunolabel categories (Table
6).
Discussion
Our observations of endometrial CLDN4 and LIF immu-
nolabeling during the luteal phase in IVF patients revealed
a specific expression profile associated with successful
pregnancy. While the role of CLDN4 in the optimization
of endometrium for implantation is not clear, our results
suggest that higher levels of CLDN4 are associated with
lower pregnancy and birth rates. In addition, our CLDN4
immunolabeling data are agreement with previous cDNA
microarray studies, wherein the frequency of strong
immunolabeling for CLDN4 peaked in the midluteal
phase, and remained high during the late luteal phase [2].
The influence of CLDN4 may be related to its presence in
tight junctions. The traffic of small solutes between differ-
ent intercellular compartments is controlled by pores in
tight junctions [21]. Indeed, a crucial intercellular com-
partment is the microenvironment between the differenti-
ating endometrium and the trophoblast. Pore selectivity is
determined by its protein composition, and CLDN4 is
one of the component proteins [9,21]. Specifically, pores
containing CLDN4 are selectively permeable to chloride
ions, and exclusive of sodium ions [22].
An increase of CLDN4 mRNA expression during the
implantation window has been reported by several
groups, and these findings support a functional role for
this tight junction protein in implantation [4-6]. At odds
with these reports, we observed that strong immunolabe-
ling of CLDN4 was associated with non-pregnancy.
Another study reported only weak endometrial CLDN4
expression in normal women during the secretory phase
[11]. A possible mechanism supporting the association of
high CLDN4 expression with non-pregnancy could be an
adverse concentration of chloride caused by an increase in
CLDN4-containing pores. Under these circumstances,
tight junctions may disadvantageously bias the sodium/
chloride regulation of the stromal paracellular milieu gov-
erned by CLDN4 pores [22].
Two studies proposed that CLDN4 and LIF are upregu-
lated by the action of progesterone [23,24]. However, our
four categories of CLDN4/LIF immunolabeling demon-
strate no association between the immunolabeling inten-
sity of these endometrial proteins. The apparent
independent expression of CLDN4 and LIF suggests that
they may be controlled by different pathways, triggered by
the balanced relationship between progesterone receptors
A and B [3] Though the expression of CLDN4 and LIF
appear unrelated, a survey of independent pathways
Table 3: Odds ratio(OR) * for pregnancy, 95% confidence interval (95%CI) and p-value (p) for CLDN4/LIF categories.
CLDN4+/LIF+ CLDN4+/LIF- CLDN4-/LIF-
CLDN4-/LIF+
(OR; 95%CI; p)
4; 0.34–47.11; 0.27 36; 2.69–481.2; 0.007 10.29; 1.02–103.95; 0.048
CLDN4+/LIF-
(OR; 95%CI; p)
0.89; 0.2–0.79; 0.028 0.71; 0.05–1.67; 0.16
CLDN4-/LIF-
(OR; 95%CI; p)
0.39; 0.08–1.87; 0.23
*Odds ratio were calculated for each category in the lines in relation to the each category in the columns.
Table 4: Odds ratio(OR)* for birth, 95% confidence interval (95% CI) and p-value (p) for CLDN4/LIF categories.
CLDN4-/LIF- CLDN4-/LIF+ CLDN4+/LIF-
CLDN4+/LIF+
(OR; 95%CI; p)
2.13; 0.42–10.73; 0.358 0.32; 0.04–2.62; 0.288 4.8; 0.65–35.2; 0.123
CLDN4+/LIF-
(OR; 95%CI; p)
0.44; 0.08–2.6; 0.368 0.07; 0.01–0.61; 0.017
CLDN4-/LIF+
(OR; 95%CI; p)
6.67; 1.01–44.10; 0.049
*Odds ratio were calculated for each category in the lines in relation to the each category in the columns.Reproductive Biology and Endocrinology 2009, 7:30 http://www.rbej.com/content/7/1/30
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related to the implantation phenomenon might be advan-
tageous for the assessment of IVF success.
In the current study, the combined assessment of
endometrial CLDN4 and LIF immunolabeling during the
luteal phase preceding an IVF treatment revealed that cer-
tain expression patterns can be predictive of pregnancy
before IVF treatment. These data also re-emphasize the
importance of LIF, as LIF+ immunolabeling is strongly
associated with a higher chance of pregnancy, an outcome
that is not affected by strong expression of CLDN4.
While the association of strong CLDN4 expression with
non-pregnancy could be related to changes in ion regula-
tion dynamics, the presence of strong LIF immunolabel
appears to reduce this association. Our data show that the
association of strong CLDN4 immunolabeling with non-
pregnancy is weakened by the strong expression of LIF
immunolabeling. Specifically, the detrimental effect of
strong CLDN4 immunolabeling is not observed in
CLDN4+/LIF+ patients. Rather, the more potent contribu-
tor to the success or failure of implantation or pregnancy
appears to be the absence of LIF, though CLDN4 does
appear to contribute in part.
In this study group of IVF patients, birth rates were highly
correlated to pregnancy rates. The frequency of births was
lower than the frequency of non-birth in patients with
CLDN4+/LIF- and CLDN4+/LIF+ immunolabel categories,
yet similar among the CLDN4-/LIF-  category. Further-
more, these frequencies of pregnancy and birth tended to
be higher in patients in the CLDN4-/LIF+ immunolabel
category. These patterns of birth frequency reflect the cor-
relation of pregnancy rates, and thus may not directly
implicate endometrial CLDN4/LIF patterns in the proc-
esses following implantation.
These results raise the question, "What are the clinical/
therapeutic implications of a CLDN4+/LIF-  profile, or
other less favorable endometrial characterizations?"
Indeed, patients undergoing infertility workup and possi-
ble Assisted Reproduction Treatment programs should be
informed of their reproductive prognosis and chances of
success or counseling. The endometrial characterization
described here may help shape expectations for these
patients. Thus, the development of subsidiary exams to
assess the endometrium alongside other factors affecting
implantation may invigorate the counseling of infertile
couples.
The therapeutic value of endometrial characterization is
not as easily defined. Our data suggest that compensation
for low LIF expression may increase pregnancy chances,
and possibly counteract equally unfavorable high levels of
endometrial CLDN4. However, controlled increase of
endometrial LIF is not yet clinically possible. The current
understanding that embryonically-derived hCG upregu-
lates expression of endometrial LIF [25], and that local
instillation of hCG increases LIF expression [26], supports
a therapeutic approach of worthy of further investigation.
Table 5: IVF parameters in the study group
Pregnant
(mean ± SD)
Non-pregnant
(mean ± SD)
Maternal age (yrs) 33.1 ± 4.17a 36.06 ± 4.7b
Number of previous IVF cycles 1.32 ± 1.36a 1.66 ± 1.12a
rFSH total dose (IU) 2476 ± 999a 2679 ± 1,000a
# transferred embryos 3.2 ± 0.8a 2.9 ± 0.9a
# top quality embryos 1 ± 1.2a 0.55 ± 0.9a
Mean score per embryo 22.8 ± 7.5a 18.7 ± 8.2a
Different letter indicate p < 0.05
rFSH total dose = amount used to accomplish ovulation induction
Table 6: IVF parameters separated into CLDN4/LIF immunolabeling categories
CLDN4+/LIF+
(mean ± SD)
CLDN4+/LIF-
(mean ± SD)
CLDN4-/LIF-
(mean ± SD)
CLDN4-/LIF+
(mean ± SD)
Maternal age (yrs) 36.5 ± 3.2 35.4 ± 4 35 ± 4 35.4 ± 5.5
# of previous IVF cycles 1.18 ± 1.04 1.65 ± 1.32 1.34 ± 1.45 1.55 ± 1.63
rFSH total dose (IU) 2340 ± 708 2609 ± 1,151 2697 ± 1028 2721 ± 1067
# of transferred embryos 3.2 ± 0.8 3 ± 0.7 3.1 ± 1 2.5 ± 0.8
# of top quality embryos 0.9 ± 0.7 0.7 ± 0.3 0.8 ± 1 0.2 ± 0.3
Mean score per embryo 21.6 ± 6.8 15.2 ± 6.9 18.2 ± 6.9 20.5 ± 8.3Reproductive Biology and Endocrinology 2009, 7:30 http://www.rbej.com/content/7/1/30
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The pattern of steroid concentration varies with age. In
both natural and stimulated cycles of younger women, the
"endometrial proteome profile" might not be similar to
those in older women, as shown for patients that did not
achieve pregnancy [21,27]. Due to ethical limitations,
biopsies of endometrial tissue from failed pregnancies are
not easily available, thus limiting a direct evaluation of
CLDN4/LIF immunolabeling in these cases. There are fur-
ther limitations on examination at the earlier timepoint of
embryo transfer. Nevertheless, a CLDN4/LIF endometrial
profile gathered from endometrial biopsies obtained dur-
ing the implantation window of a spontaneous cycle
could generate a useful criteria for an endometrium that is
optimal for implantation. Clinical comparison to
endometrial biopsies following ovarian stimulation
would help forecast pregnancy success after an IVF treat-
ment.
As observations from clinical research can often provide
valuable feedback for basic research, our data may help
researchers who optimize Assisted Reproduction Technol-
ogy, or those working in basic areas in Reproductive Biol-
ogy. We report these data with the hope that they will also
support the generation of new research questions and
therapeutic innovations, in the sprit of Translational Med-
icine.
Conclusion
Determination of the relative endometrial CLDN4/LIF
expression in a spontaneous menstrual cycle preceding an
IVF treatment can be used as a biomarker of endometrial
receptivity.
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